Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBITDA (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed EBITDA for 14 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 181.13% year-over-year to -$2.9 million, compared with a TTM value of -$20.2 million through Dec 2025, down 48.78%, and an annual FY2025 reading of -$20.2 million, down 48.78% over the prior year.
  • EBITDA was -$2.9 million for Q4 2025 at Heron Therapeutics, up from -$17.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $3.6 million in Q4 2024 and bottomed at -$63.9 million in Q1 2022.
  • Average EBITDA over 5 years is -$27.4 million, with a median of -$22.4 million recorded in 2022.
  • Peak annual rise in EBITDA hit 182.51% in 2025, while the deepest fall reached 264.46% in 2025.
  • Year by year, EBITDA stood at -$54.6 million in 2021, then soared by 63.71% to -$19.8 million in 2022, then soared by 45.99% to -$10.7 million in 2023, then soared by 133.95% to $3.6 million in 2024, then crashed by 181.13% to -$2.9 million in 2025.
  • Business Quant data shows EBITDA for HRTX at -$2.9 million in Q4 2025, -$17.5 million in Q3 2025, and -$2.4 million in Q2 2025.